Vera Therapeutics, Inc. (VERA) · Sep 15, 2026 · Other events

Vera Therapeutics posts 76% kidney-risk reduction, backing full TRUTAKNA approval

Above the bar — 76% composite kidney-progression risk reduction; 5.0 mL/min/1.73m²/year eGFR-slope benefit vs placebo

Vera’s final ORIGIN 3 readout adds durable eGFR and kidney-progression benefits to TRUTAKNA’s approval case, clearing the key confirmatory hurdle.

Vera is now a commercial-stage biotech launching accelerated-approved TRUTAKNA for IgA nephropathy, but its business still hinges on converting that conditional approval into full approval through ORIGIN 3 kidney-function data. The timing of this final analysis and a Q4 2026 supplemental filing was already disclosed, so the surprise is the strength of the evidence rather than the existence of the event.

The confirmatory readout materially strengthens the approval case. The filing says TRUTAKNA met all predefined endpoints, including placebo-adjusted eGFR and composite kidney-progression benefits.

ORIGIN 3 final resultTRUTAKNAPlacebo / comparisonFiling location
Mean eGFR change at 52 weeks-0.1 mL/min/1.73m²-5.7; placebo-adjusted difference 5.6(ORIGIN 3 final efficacy analysis)
Annualized eGFR slope through 104 weeks-0.6 mL/min/1.73m²/year-5.6; placebo-adjusted difference 5.0(ORIGIN 3 final efficacy analysis)
Composite kidney-progression events5%18%(Composite kidney progression endpoint)
Risk reduction in composite endpoint76%Hazard ratio 0.24(Composite kidney progression endpoint)

This moves TRUTAKNA from a proteinuria story toward a disease-modifying kidney story. The earlier interim result had already shown a 42% placebo-adjusted reduction in proteinuria, but the final analysis now shows kidney-function preservation through 104 weeks and fewer composite progression events. That is the evidence Vera needed to support its planned sBLA, not merely a repeat of the accelerated-approval surrogate.

Safety looks manageable, but not frictionless. Serious adverse events and discontinuations were numerically lower with TRUTAKNA than placebo, while infections were similar; the trade-off was a higher rate of injection-site reactions and study-drug-related adverse events. The filing describes the overall profile as generally comparable to placebo.

The regulatory path is now clearer, not complete. Vera still needs to submit the supplemental BLA in Q4 2026 and obtain FDA review for full approval; the filing supports that path but does not itself grant the approval. The commercial launch is therefore backed by a substantially stronger clinical package, while the next value-bearing milestone remains regulatory conversion from accelerated to full approval.

Bottom line: This is a meaningful upgrade to Vera’s core story: TRUTAKNA now has confirmatory kidney-function and progression data behind its accelerated approval. The filing turns full approval from a promising possibility into a well-supported next regulatory step, though FDA action is still required.

What to watch next

sBLA submission for full approval, Q4 2026

Original filing on SEC EDGAR

More Vera Therapeutics, Inc. news

Vera Therapeutics posts 76% kidney-risk reduction, backing full TRUTAKNA approval | VERA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.